Home » WorldHeart Receives Unconditional BTT Study Approval for Levacor VAD
WorldHeart Receives Unconditional BTT Study Approval for Levacor VAD
World Heart Corporation, a developer of mechanical circulatory systems,
announced Monday that it has received unconditional approval from the U.S. Food and Drug Administration for the bridge-to-transplant study of the Levacor
Ventricular Assist Device (VAD).
Utah Pulse
Utah Pulse
Upcoming Events
-
07May
-
14May
-
30May